A multi-center phase I/II study of melphalan, prednisone, thalidomide and defibrotide in avanced multiple myeloma patients.

被引：3
|
作者：
Palumbo, Antonio
Rus, Cecilia
Rossi, Davide
Pregno, Patrizia
Ambrosini, Maria Teresa
Avonto, Ilaria
Gay, Francesca
Cavallo, Federica
Iacobelli, Massimo
Gaidano, Gianluca
Mitsiades, Constantine
Richardson, Paul G.
Anderson, Kenneth C.
Boccadoro, Mario
机构：
[1] Univ Turin, Azienda Osped San Giovanni Battista, Div Ematol, Turin, Italy
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.3560.3560
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3560
引用
收藏
页码：1016A / 1017A
页数：2
相关论文
共 50 条
  • [31] BORTEZOMIB, MELPHALAN, PREDNISONE AND THALIDOMIDE (VMPT) VERSUS BORTEZOMIB, MELPHALAN AND PREDNISONE (VMP) IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS: A PROSPECTIVE, RANDOMIZED, PHASE III STUDY
    Palumbo, A.
    Bringhen, S.
    Rossi, D.
    Ria, R.
    Berretta, S.
    Offidani, M.
    Patriarca, F.
    Nozzoli, C.
    Levi, A.
    Guglielmelli, T.
    Benevolo, G.
    Callea, V.
    Liberati, A. M.
    Crippa, C.
    Di Renzo, N.
    Catalano, L.
    De Sabbata, G.
    Rizzi, R.
    Feo, C.
    Mazza, R.
    Farina, G.
    Spadano, A.
    Pisani, F.
    Podda, L.
    Aitoro, G.
    Magarotto, V.
    Astolfi, M.
    Di Raimondo, F.
    Gaidano, G.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 190 - 191
  • [32] Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation
    Roy, V.
    Stewart, A. K.
    Bergsagel, P. L.
    Dispenzieri, A.
    Laumann, K.
    Allred, J.
    Lacy, M. Q.
    Fonseca, R.
    Reeder, C. B.
    Kumar, S.
    Rivera, C. E.
    Gertz, M. A.
    Buadi, F. K.
    Hayman, S. R.
    Rajkumar, S. V.
    BLOOD CANCER JOURNAL, 2015, 5 : e294 - e294
  • [33] Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation
    V Roy
    A K Stewart
    P L Bergsagel
    A Dispenzieri
    K Laumann
    J Allred
    M Q Lacy
    R Fonseca
    C B Reeder
    S Kumar
    C E Rivera
    M A Gertz
    F K Buadi
    S R Hayman
    S V Rajkumar
    Blood Cancer Journal, 2015, 5 : e294 - e294
  • [34] Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial
    Palumbo, A
    Bringhen, S
    Coravito, T
    Merla, E
    Capporella, V
    Callea, V
    Cangialosi, C
    Grasso, M
    Rossini, F
    Galli, M
    Catalano, L
    Zamagni, E
    Petrucci, MT
    De Stefano, V
    Ceccarelli, M
    Ambrosini, MT
    Avonto, I
    Falco, P
    Ciccone, G
    Liberati, AM
    Musto, P
    Boccadoro, M
    LANCET, 2006, 367 (9513): : 825 - 831
  • [35] THALIDOMIDE PLUS MELPHALAN AND PREDNISONE FOR AUSTRALIAN PATIENTS NEWLY DIAGNOSED WITH MULTIPLE MYELOMA IS COST-EFFECTIVE WHEN COMPARED WITH MELPHALAN AND PREDNISONE ALONE
    Lourenco, De Abreu R.
    Colman, S.
    Lee, C.
    VALUE IN HEALTH, 2009, 12 (07) : A381 - A381
  • [36] Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients
    Palumbo, Antonio
    Bringhen, Sara
    Rossi, Davide
    Ria, Roberto
    Offidani, Massimo
    Patriarca, Francesca
    Nozzoli, Chiara
    Levi, Anna
    Guglielmelli, Tommasina
    Benevolo, Giulia
    Callea, Vincenzo
    Olivero, Barbara
    Morabito, Fortunato
    Grasso, Mariella
    Marasca, Roberto
    Rizzo, Manuela
    Falcone, Antonietta Pia
    Gottardi, Daniela
    Montefusco, Vittorio
    Musolino, Caterina
    Zambello, Renato
    Cangialosi, Clotilde
    Pietrantuono, Giuseppe
    Magarotto, Valeria
    Petrucci, Maria Teresa
    Musto, Pellegrino
    Ciccone, Giovannino
    Di Raimondo, Francesco
    Gaidano, Gianluca
    Boccadoro, Mario
    BLOOD, 2009, 114 (22) : 58 - 58
  • [37] VAMP/ThaCyDex: Velcade® (Bortezomib), Adriamycin, Melphalan and Prednisone Alternating with Thalidomide, Cyclophosphamide and Dexametasone as a Salvage Regimen in Relapsed Multiple Myeloma Patients.
    Colado, Enrique
    Mateos, Maria-Victoria
    Moreno, Maria-Jose
    Dearriba, Felipe
    de la Rubia, Javier
    Lahuerta, Juan Jose
    Iniesta, Pastora
    Viguria, Maria Cruz
    Gonzalez, Ana Pilar
    Garcia-Sanz, Ramon
    Olazabal, Juan
    Miguel, Jesus F. San
    BLOOD, 2008, 112 (11) : 1265 - 1266
  • [38] A PHASE III STUDY COMPARING THALIDOMIDE/CYCLOPHOSPHAMIDE/DEXA VS THALIDOMIDE/DEXA VS THALIDOMIDE/MELPHALAN/PREDNISONE IN DE NOVO MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT: PRELIMINARY ANALYSIS
    Hungria, V.
    Crusoe, E.
    Maiolino, A.
    Bittencourt, R.
    Fantl, D.
    Ouero, A.
    Peres, A. L.
    Mercante, D.
    Miranda, E.
    Chiattone, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 148 - 148
  • [39] Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma - a retrospective population based study of 1162 patients
    Lund, Johan
    Uttervall, Katarina
    Liwing, Johan
    Gahrton, Gosta
    Alici, Evren
    Aschan, Johan
    Holmberg, Erik
    Nahi, Hareth
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 92 (01) : 19 - 25
  • [40] Melphalan- prednisone-thalidomide (MPT), a new reference treatment in elderly patients with multiple myeloma?
    Gastinne, Thomas
    Leleu, Xavier
    HEMATOLOGIE, 2007, 13 (06): : 384 - 385
12345